A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity - Scorecard - MDSpire

A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity

  • By

  • Arianna Sartori

  • Anna Favero

  • Laura Mazzari

  • Giulia Mazzon

  • Alessio Bratina

  • Antonio Bosco

  • Marinella Tomaselli

  • Paolo Manganotti

  • June 16, 2026

  • 0 min

Share

Clinical Scorecard: Integrative Treatment Strategy: Utilizing Extracorporeal Shock Wave Therapy Alongside Botulinum Toxin for Spasticity in Multiple Sclerosis

At a Glance

CategoryDetail
Condition
Key MechanismsReduced acetylcholine release, increased nitric oxide production, and clarify anti-inflammatory effects with citations.
Target Population
Care Setting

Key Highlights

  • add_statistical_significance

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • d
      • e
      • t
      • a
      • i
      • l
      • e
      • d
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • p
      • r
      • o
      • t
      • o
      • c
      • o
      • l
      • s
      • a
      • n
      • d
      • c
      • l
      • a
      • r
      • i
      • f
      • y
      • r
      • i
      • s
      • k
      • s
      • a
      • s
      • s
      • o
      • c
      • i
      • a
      • t
      • e
      • d
      • w
      • i
      • t
      • h
      • f
      • E
      • S
      • W
      • T
      • .

      Risks

        Patient & Prescribing Data

        Specify the treatment protocol for fESWT and botulinum toxin.

        Clinical Best Practices

        • expand_monitoring

        Related Resources & Content

        Original Source(s)

        A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity

        • by Arianna Sartori, Anna Favero, Laura Mazzari, Giulia Mazzon, Alessio Bratina, Antonio Bosco, Marinella Tomaselli, Paolo Manganotti

        • June 16, 2026

        Related Content

        When Bad Data Enters the Drug Pipeline

        Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

        FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

        The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

        Case Study: Ofatumumab-Induced Remission in Refractory Panuveitis Accompanied by Multiple Sclerosis